SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-045074
Filing Date
2023-12-15
Accepted
2023-12-15 17:00:38
Documents
14
Period of Report
2023-12-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43569
2 ex10-1.htm EX-10.1 47138
  Complete submission text file 0001493152-23-045074.txt   324617

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bfri-20231212.xsd EX-101.SCH 3967
4 XBRL DEFINITION FILE bfri-20231212_def.xml EX-101.DEF 27426
5 XBRL LABEL FILE bfri-20231212_lab.xml EX-101.LAB 37912
6 XBRL PRESENTATION FILE bfri-20231212_pre.xml EX-101.PRE 26043
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6232
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

IRS No.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 231491183
SIC: 2834 Pharmaceutical Preparations